open access

Vol 15, No 3 (2019)
Other materials agreed with the Editors
Published online: 2019-06-26
Get Citation

Current literature review

Maciej Kawecki
DOI: 10.5603/OCP.2019.0023
·
Oncol Clin Pract 2019;15(3):190-193.

open access

Vol 15, No 3 (2019)
CURRENT LITERATURE REVIEW
Published online: 2019-06-26

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Current literature review

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 3 (2019)

Article type

Other materials agreed with the Editors

Pages

190-193

Published online

2019-06-26

DOI

10.5603/OCP.2019.0023

Bibliographic record

Oncol Clin Pract 2019;15(3):190-193.

Authors

Maciej Kawecki

References (6)
  1. Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817–1825.
  2. Dahan L, Phelip J, Malicot KLe, et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). Journal of Clinical Oncology. 2018; 36(15_suppl): 4000.
  3. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline-mutated metastatic pancreatic cancer. N Engl J Med. 2019 [Epub ahead of print].
  4. Hall P, Swinson D, Waters J, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. Journal of Clinical Oncology. 2019; 37(15_suppl): 4006.
  5. Buckner J, Shaw E, Pugh S, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. New England Journal of Medicine. 2016; 374(14): 1344–1355.
  6. Bell E, Won M, Fleming J, et al. Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802. J Clin Oncol. 2019; 37(15_suppl): 2002.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl